2020 Q4 IngenioRx Drug and Biologic Pipeline Update

Download our Q4 2020 IngenioRx Drug and Biologic Pipeline Update – an essential read for understanding how the drug and biologic pipeline could unfold in the coming months.  Providing our own insight and analysis, some highlights of this edition include:

• An examination of a first-of-its-kind therapy to possibly slow clinical decline in patients with Alzheimer’s disease 
• In-depth reviews of proposed treatments for uterine fibroids and a rare metabolic disease in children
• An analysis of how and why specialty drugs are prominent in the pipeline
• Market trends likely affecting the pipeline and the state of gene therapies